Patent Docs is a new weblog focusing on recent developments in biotech and pharma patent law. This weblog will offer updates regarding changes in Patent Office rules and procedures affecting biotech and pharma patent prosecution, and provide summaries of recent court and board decisions impacting biotech and pharma patent litigation and prosecution. In addition, Patent Docs will report on biotech and pharma news and highlight newly issued biotech and pharma patents. The news and information presented on Patent Docs is provided by a group of patent practitioners holding doctorates in a diverse array of biotech and chemical disciplines.
Contributors
Juristat #4 Overall Rank
Contact the Docs
Foreign Correspondents
Recent Posts
- Supreme Court Denies Certiorari in Cellect v. Vidal
- In re Cellect in View of Supreme Court's "Long Conference" – Part II
- In re Cellect in View of Supreme Court's "Long Conference"
- Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (Fed. Cir. 2024)
- Astellas Pharma, Inc. v. Sandoz Inc. (Fed. Cir. 2024)
- Wisconsin Alumni Research Foundation v. Apple Inc. (Fed. Cir. 2024)
- Special Committee's Suspension Recommendation Adopted by Federal Circuit
- Natera, Inc. v. NeoGenomics Laboratories, Inc. (Fed. Cir. 2024)
- Andersen v. Stability AI: Defendants' Motion to Dismiss Narrows the Case, But Only Slightly
- Ryan LLC v. FTC: Texas Federal Court Strikes Down FTC's Prohibition on Non-Competes
Disclaimer
- "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank
- Powered By Invesp
October 2024
Categories
- Artificial Intelligence (19)
- Best Mode (2)
- Biosimilars (247)
- Biotech/Pharma Business (175)
- Biotech/Pharma News (277)
- Board of Patent Appeals and Interferences (12)
- Claim Construction (104)
- Conferences & CLE's (2977)
- Copyright (4)
- Court Report (507)
- Damages (37)
- Definiteness (26)
- District Court (222)
- Double Patenting (40)
- Enablement (52)
- Federal Circuit (1017)
- Food and Drug Administration (109)
- Hatch-Waxman (93)
- Inequitable Conduct (52)
- Infringement - Contributory or Induced (28)
- Infringement - Literal or DOE (91)
- Injunction (34)
- International IP (297)
- Inventorship (17)
- Licensing (129)
- Media Commentary (71)
- Miscellaneous (168)
- News from Abroad (102)
- Novelty (73)
- Obviousness (233)
- Patent Exhaustion (3)
- Patent Legislation (312)
- Patent Litigation (217)
- Patent Office Rules & Procedures (827)
- Patent Profiles (104)
- Patent Prosecution (99)
- Patent Prosecution - International (26)
- Patent Research (4)
- Patent Trial and Appeal Board (369)
- Patentable Subject Matter (644)
- Personalized Medicine (5)
- Post-Grant Proceedings (158)
- PTAB Report (9)
- Study/Report (7)
- Supreme Court (265)
- Tools (5)
- Trade Secrets (13)
- Utility (4)
- Venue (11)
- Written Description (88)
Patent Resources
Patent Search
- Patent Search
Patent Blogs & Sites
- 717 Madison Place
- America-Israel Patent Law
- Anticipate This!
- BlawgIT
- Chicago IP Litigation Blog
- FedCircuitBlog
- Global Patent Quality
- Innovation Alliance
- Intellectual Property Watch
- IP Dragon
- IPcopy
- McCabe Ali LLP
- IPWatchdog.com
- Life Science IP
- Orange Book Blog
- Patent Blurb
- Patently-O
- Patentology
- Patents4Life
- Reexamination Center
- Intellepedia – IP News Center
- SPICY IP
Comments